JP2017081856A - 骨形成促進剤及び骨形成促進装置 - Google Patents
骨形成促進剤及び骨形成促進装置 Download PDFInfo
- Publication number
- JP2017081856A JP2017081856A JP2015212328A JP2015212328A JP2017081856A JP 2017081856 A JP2017081856 A JP 2017081856A JP 2015212328 A JP2015212328 A JP 2015212328A JP 2015212328 A JP2015212328 A JP 2015212328A JP 2017081856 A JP2017081856 A JP 2017081856A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- lactic acid
- ligand
- test
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000011164 ossification Effects 0.000 title claims abstract description 74
- 230000001737 promoting effect Effects 0.000 title claims abstract description 33
- 239000003446 ligand Substances 0.000 claims abstract description 77
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 54
- 239000000556 agonist Substances 0.000 claims abstract description 50
- 101000843810 Homo sapiens Hydroxycarboxylic acid receptor 1 Proteins 0.000 claims abstract description 48
- 102100030642 Hydroxycarboxylic acid receptor 1 Human genes 0.000 claims abstract description 48
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims abstract description 28
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 26
- 239000004310 lactic acid Substances 0.000 claims abstract description 26
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical compound CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000002243 precursor Substances 0.000 claims abstract description 23
- 239000004480 active ingredient Substances 0.000 claims abstract description 20
- BWLBGMIXKSTLSX-UHFFFAOYSA-N 2-hydroxyisobutyric acid Chemical compound CC(C)(O)C(O)=O BWLBGMIXKSTLSX-UHFFFAOYSA-N 0.000 claims abstract description 12
- NGEWQZIDQIYUNV-UHFFFAOYSA-N L-valinic acid Natural products CC(C)C(O)C(O)=O NGEWQZIDQIYUNV-UHFFFAOYSA-N 0.000 claims abstract description 12
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims abstract description 12
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims abstract description 12
- 239000011976 maleic acid Substances 0.000 claims abstract description 12
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 12
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims abstract description 10
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 claims abstract description 8
- NYHNVHGFPZAZGA-UHFFFAOYSA-N 2-hydroxyhexanoic acid Chemical compound CCCCC(O)C(O)=O NYHNVHGFPZAZGA-UHFFFAOYSA-N 0.000 claims abstract description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims abstract description 5
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000019260 propionic acid Nutrition 0.000 claims abstract description 5
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims abstract description 5
- 239000011975 tartaric acid Substances 0.000 claims abstract description 5
- 235000002906 tartaric acid Nutrition 0.000 claims abstract description 5
- 229920000642 polymer Polymers 0.000 claims description 61
- 238000000034 method Methods 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 29
- 238000005227 gel permeation chromatography Methods 0.000 claims description 25
- 239000007924 injection Substances 0.000 claims description 20
- 238000002347 injection Methods 0.000 claims description 20
- 238000005259 measurement Methods 0.000 claims description 16
- 239000004793 Polystyrene Substances 0.000 claims description 8
- 229920002223 polystyrene Polymers 0.000 claims description 8
- 230000009969 flowable effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 50
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 186
- 238000012360 testing method Methods 0.000 description 95
- 210000004027 cell Anatomy 0.000 description 80
- 230000002308 calcification Effects 0.000 description 55
- 210000000963 osteoblast Anatomy 0.000 description 39
- 230000000694 effects Effects 0.000 description 38
- 238000010186 staining Methods 0.000 description 34
- 238000007792 addition Methods 0.000 description 28
- 229960000448 lactic acid Drugs 0.000 description 24
- JKYKXTRKURYNGW-UHFFFAOYSA-N 3,4-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-sulfonic acid Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(O)=C(O)C(S(O)(=O)=O)=C2 JKYKXTRKURYNGW-UHFFFAOYSA-N 0.000 description 23
- 229920001432 poly(L-lactide) Polymers 0.000 description 21
- 229920001577 copolymer Polymers 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 238000004113 cell culture Methods 0.000 description 13
- 239000012530 fluid Substances 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 102000052402 Monocarboxylate transporter 1 Human genes 0.000 description 11
- 108700038057 Monocarboxylate transporter 1 Proteins 0.000 description 11
- 230000033558 biomineral tissue development Effects 0.000 description 10
- 210000000988 bone and bone Anatomy 0.000 description 10
- 238000004043 dyeing Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 102000008186 Collagen Human genes 0.000 description 9
- 108010035532 Collagen Proteins 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 229920001436 collagen Polymers 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000004055 small Interfering RNA Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 230000001133 acceleration Effects 0.000 description 7
- 230000010478 bone regeneration Effects 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229920000747 poly(lactic acid) Polymers 0.000 description 6
- 239000004626 polylactic acid Substances 0.000 description 6
- 210000003625 skull Anatomy 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 102000012422 Collagen Type I Human genes 0.000 description 5
- 108010022452 Collagen Type I Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000006116 polymerization reaction Methods 0.000 description 5
- AFVLVVWMAFSXCK-UHFFFAOYSA-N α-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(C#N)=CC1=CC=C(O)C=C1 AFVLVVWMAFSXCK-UHFFFAOYSA-N 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 4
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 239000010419 fine particle Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 229940107700 pyruvic acid Drugs 0.000 description 4
- 210000004872 soft tissue Anatomy 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 208000020084 Bone disease Diseases 0.000 description 3
- 102000001187 Collagen Type III Human genes 0.000 description 3
- 108010069502 Collagen Type III Proteins 0.000 description 3
- 108091027967 Small hairpin RNA Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 125000003636 chemical group Chemical group 0.000 description 3
- 230000037319 collagen production Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000007334 copolymerization reaction Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229920001519 homopolymer Polymers 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 241000725101 Clea Species 0.000 description 2
- 229930182843 D-Lactic acid Natural products 0.000 description 2
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- -1 L-lactic acid) Chemical compound 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940022769 d- lactic acid Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000002188 osteogenic effect Effects 0.000 description 2
- 239000012925 reference material Substances 0.000 description 2
- 102000037983 regulatory factors Human genes 0.000 description 2
- 108091008025 regulatory factors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- GAWAYYRQGQZKCR-UHFFFAOYSA-N 2-chloropropionic acid Chemical compound CC(Cl)C(O)=O GAWAYYRQGQZKCR-UHFFFAOYSA-N 0.000 description 1
- CMELCQNRYRDZTG-UHFFFAOYSA-N 3-hydroxybutanoic acid Chemical compound CC(O)CC(O)=O.CC(O)CC(O)=O CMELCQNRYRDZTG-UHFFFAOYSA-N 0.000 description 1
- HZYZHUZIWFRBNU-UHFFFAOYSA-N 4-hydroxybutanoic acid Chemical compound OCCCC(O)=O.OCCCC(O)=O HZYZHUZIWFRBNU-UHFFFAOYSA-N 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 206010009269 Cleft palate Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 238000012648 alternating copolymerization Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000012661 block copolymerization Methods 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 101150065676 mct gene Proteins 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 210000004663 osteoprogenitor cell Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Surgical Instruments (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
[1]GPR81のリガンド、アゴニスト及びこれらの前駆体からなる群より選択される1以上を有効成分として含むことを特徴とする骨形成促進剤。
[2]前記リガンドは、乳酸、α−ヒドロキシ酪酸、γ−ヒドロキシ酪酸、α−ヒドロキシイソ酪酸、グリコール酸、α−ヒドロキシカプロン酸、マレイン酸、酒石酸及びプロピオン酸からなる群より選択される1以上である上記[1]記載の骨形成促進剤。
[3]前記リガンドは、乳酸である上記[1]又は[2]記載の骨形成促進剤。
[4]前記前駆体は、前記リガンド又は前記アゴニストを含む成分の重合体である上記[1]乃至[3]のいずれかに記載の骨形成促進剤。
[5]前記重合体は、次の(a)及び/又は(b)を満たす:(a)ゲル浸透クロマトグラフィー法により測定されるポリスチレン換算の数平均分子量が300〜2000の範囲内である;(b)ゲル浸透クロマトグラフィー法による測定で得られるクロマトグラムにおいて、全面積に対する、ポリスチレン換算の分子量250〜2000の範囲の面積の割合が50%〜100%の範囲内である;上記[4]記載の骨形成促進剤。
[6]流動性組成物である上記[1]乃至[5]のいずれかに記載の骨形成促進剤。
[7]注入用組成物である上記[1]乃至[6]のいずれかに記載の骨形成促進剤。
[8]上記[6]又は[7]に記載の骨形成促進剤を収容するリザーバ部と、前記リザーバ部の前記骨形成促進剤を患者の患部に注入する注入部と、を備えたことを特徴とする骨形成促進装置。
・測定装置:高速GPC装置 HLC−8120(東ソー株式会社製)
・GPCカラム:TSKgel G6000HXL、G5000HXL、G4000HXL、G2500HXL、G1000HXL、TSK guard column HXL-H(いずれも東ソー株式会社製、TSK guard column HXL-H以外は7.8mmI.D.×30cmL)
・ポリスチレン基準物質:F-128(1.09×106)、F-80(7.06×105)、F-40(4.27×105)、F-20(1.90×105)、F-10(9.64×104)、F-4(3.79×104)、F-2(1.81×104)、F-1(1.02×104)、A-5000(5.97×103)、A-2500(2.63×103)、A-1000(1.01×103)、A-500(5.0×102)(いずれも東ソー株式会社製) ※( )内は分子量の代表的値
・カラム温度:40℃付近の一定温度
・移動相:THF
・流量:0.8mL/min
Claims (8)
- GPR81のリガンド、アゴニスト及びこれらの前駆体からなる群より選択される1以上を有効成分として含む
ことを特徴とする骨形成促進剤。 - 前記リガンドは、乳酸、α−ヒドロキシ酪酸、γ−ヒドロキシ酪酸、α−ヒドロキシイソ酪酸、グリコール酸、α−ヒドロキシカプロン酸、マレイン酸、酒石酸及びプロピオン酸からなる群より選択される1以上である
ことを特徴とする請求項1に記載の骨形成促進剤。 - 前記リガンドは、乳酸である
ことを特徴とする請求項1又は2に記載の骨形成促進剤。 - 前記前駆体は、前記リガンド又は前記アゴニストを含む成分の重合体である
ことを特徴とする請求項1乃至3のいずれかに記載の骨形成促進剤。 - 前記重合体は、次の(a)及び/又は(b)を満たす:
(a)ゲル浸透クロマトグラフィー法により測定されるポリスチレン換算の数平均分子量が300〜2000の範囲内である;
(b)ゲル浸透クロマトグラフィー法による測定で得られるクロマトグラムにおいて、全面積に対する、ポリスチレン換算の分子量250〜2000の範囲の面積の割合が50%〜100%の範囲内である;
ことを特徴とする請求項4に記載の骨形成促進剤。 - 流動性組成物である
ことを特徴とする請求項1乃至5のいずれかに記載の骨形成促進剤。 - 注入用組成物である
ことを特徴とする請求項1乃至6のいずれかに記載の骨形成促進剤。 - 請求項6又は7に記載の骨形成促進剤を収容するリザーバ部と、
前記リザーバ部の前記骨形成促進剤を患者の患部に注入する注入部と、
を備えたことを特徴とする骨形成促進装置。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015212328A JP6614916B2 (ja) | 2015-10-28 | 2015-10-28 | 骨形成促進剤及び骨形成促進装置 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015212328A JP6614916B2 (ja) | 2015-10-28 | 2015-10-28 | 骨形成促進剤及び骨形成促進装置 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017081856A true JP2017081856A (ja) | 2017-05-18 |
JP6614916B2 JP6614916B2 (ja) | 2019-12-04 |
Family
ID=58712691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015212328A Active JP6614916B2 (ja) | 2015-10-28 | 2015-10-28 | 骨形成促進剤及び骨形成促進装置 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6614916B2 (ja) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02203861A (ja) * | 1989-01-31 | 1990-08-13 | Taki Chem Co Ltd | 生体材料 |
JPH0345265A (ja) * | 1989-07-12 | 1991-02-26 | Taki Chem Co Ltd | 医用組成物 |
JP2007503852A (ja) * | 2003-08-20 | 2007-03-01 | ヒストジェニックス コーポレイション | 関節軟骨、骨、骨軟骨の欠損及び傷害を治療するための非細胞基質インプラント及びその使用方法 |
WO2008063321A2 (en) * | 2006-10-13 | 2008-05-29 | Janssen Pharmaceutica N.V. | Gpr81-ligand complexes and their preparation and use |
JP2009178391A (ja) * | 2008-01-31 | 2009-08-13 | Olympus Terumo Biomaterials Corp | 骨補填材 |
JP2014050441A (ja) * | 2012-09-05 | 2014-03-20 | Nagoya Institute Of Technology | 骨形成誘導材料、及び骨形成誘導材料の製造方法 |
-
2015
- 2015-10-28 JP JP2015212328A patent/JP6614916B2/ja active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02203861A (ja) * | 1989-01-31 | 1990-08-13 | Taki Chem Co Ltd | 生体材料 |
JPH0345265A (ja) * | 1989-07-12 | 1991-02-26 | Taki Chem Co Ltd | 医用組成物 |
JP2007503852A (ja) * | 2003-08-20 | 2007-03-01 | ヒストジェニックス コーポレイション | 関節軟骨、骨、骨軟骨の欠損及び傷害を治療するための非細胞基質インプラント及びその使用方法 |
WO2008063321A2 (en) * | 2006-10-13 | 2008-05-29 | Janssen Pharmaceutica N.V. | Gpr81-ligand complexes and their preparation and use |
JP2009178391A (ja) * | 2008-01-31 | 2009-08-13 | Olympus Terumo Biomaterials Corp | 骨補填材 |
JP2014050441A (ja) * | 2012-09-05 | 2014-03-20 | Nagoya Institute Of Technology | 骨形成誘導材料、及び骨形成誘導材料の製造方法 |
Non-Patent Citations (4)
Title |
---|
ACS APPL. MATER. INTERFACES, vol. 6, JPN6019010961, 2014, pages 20895 - 20903, ISSN: 0004096939 * |
J. ORAL MAXILLOFAC. SURG., vol. 49, JPN6019010957, 1991, pages 1305 - 1309, ISSN: 0004096937 * |
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PARTA, JPN6019010959, 15 November 2006 (2006-11-15), pages 94 - 102, ISSN: 0004096938 * |
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 284, no. 5, JPN6019010963, 30 January 2009 (2009-01-30), pages 2811 - 2822, ISSN: 0004096936 * |
Also Published As
Publication number | Publication date |
---|---|
JP6614916B2 (ja) | 2019-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bai et al. | 3D printed porous biomimetic composition sustained release zoledronate to promote osteointegration of osteoporotic defects | |
Lee et al. | Dual actions of osteoclastic-inhibition and osteogenic-stimulation through strontium-releasing bioactive nanoscale cement imply biomaterial-enabled osteoporosis therapy | |
Laschke et al. | Incorporation of growth factor containing Matrigel promotes vascularization of porous PLGA scaffolds | |
Woo et al. | Synergistic effects of dimethyloxalylglycine and butyrate incorporated into α-calcium sulfate on bone regeneration | |
DK2465537T3 (en) | MICROSPHERE INCLUDING ONO-1301 | |
Ao et al. | Fibrin glue/fibronectin/heparin-based delivery system of BMP2 induces osteogenesis in MC3T3-E1 cells and bone formation in rat calvarial critical-sized defects | |
EP2898902A1 (en) | Advanced heart failure treatment material as myocardial/cardiovascular regeneration device | |
JP2005036007A (ja) | トロンビン由来ペプチドを使用した治療法 | |
Gniesmer et al. | In vivo analysis of vascularization and biocompatibility of electrospun polycaprolactone fibre mats in the rat femur chamber | |
Moeinzadeh et al. | In-situ stable injectable collagen-based hydrogels for cell and growth factor delivery | |
Orth et al. | Effects of locally applied adipose tissue-derived microvascular fragments by thermoresponsive hydrogel on bone healing | |
Lin et al. | Orchestration of energy metabolism and osteogenesis by Mg2+ facilitates low-dose BMP-2-driven regeneration | |
Santo et al. | Cell engineering by the internalization of bioinstructive micelles for enhanced bone regeneration | |
Wang et al. | Incorporation of bone morphogenetic protein-2 and osteoprotegerin in 3D-printed Ti6Al4V scaffolds enhances osseointegration under osteoporotic conditions | |
Jung et al. | Modulation of the resorption and osteoconductivity of α-calcium sulfate by histone deacetylase inhibitors | |
Farrell et al. | Effect of ibuprofen on tumor growth in the C6 spheroid implantation glioma model | |
Park et al. | Enhancement of the osteogenic efficacy of osteoblast transplantation by the sustained delivery of basic fibroblast growth factor | |
Li et al. | Roles and mechanisms of irisin in attenuating pathological features of osteoarthritis | |
Wang et al. | 3D printed integrated bionic oxygenated scaffold for bone regeneration | |
Di-Silvio | A novel application of two biomaterials for the delivery of growth hormone and its effect on osteoblasts | |
Cao et al. | 3D-printed vascularized biofunctional scaffold for bone regeneration | |
Tao et al. | Co-modification of calcium phosphate cement to achieve rapid bone regeneration in osteoporotic femoral condyle defect with lithium and aspirin | |
JP6614916B2 (ja) | 骨形成促進剤及び骨形成促進装置 | |
Huang et al. | Melatonin having therapeutic bone regenerating capacity in biomaterials | |
Wang et al. | Locally delivered metabolite derivative promotes bone regeneration in aged mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180726 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190322 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190402 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190516 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190820 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191002 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191023 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191105 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6614916 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |